ClinicalTrials.gg
TerminatedNCT00071253Updated Aug 4, 2006

Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

A Phase 4 interventional study of Divalproex Sodium (Delayed-Release Tablets) and Divalproex Sodium (Extended-Release Tablets) in Bipolar Disorder, sponsored by Abbott. Terminated at 15 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2006-08-04.

Sponsored by Abbott · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing olanzapine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Olanzapine · Bipolar Disorder.

Enrollment
7th of 28
180 · median 120
Started
2003
with 2 others
Phase 4
19 of 28
none open now
Registered
3rd of 28
by date
Lead sponsor
1 of 28
Abbott

Among the 28 studies testing olanzapine in Bipolar Disorder, this one is the 7th largest by enrollment, is one of 3 that started in 2003, is one of 19 in phase 4, and was the 3rd registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 28 studies testing olanzapine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing olanzapine in Bipolar Disorder as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of continued combination therapy using Depakote plus olanzapine, vs. Depakote monotherapy and olanzapine monotherapy in stable subjects during the maintenance phase of bipolar illness.

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Bipolar Disorder - Mania
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • primary diagnosis of Bipolar I Disorder as confirmed by the SCID
  • Outpatient receiving treatment with a combination of Depakote plus olanzapine for their bipolar illness and considered clinically stable (e.g., no more than minimal symptoms, no psychiatric hospitalizations, no increase in intensity of clinical interventions) for the preceding 4 months
  • Identified at Screening a most bothersome side effect listed in the UKU which makes switching to monotherapy desirable
  • MRS total score \< 12 on two consecutive ratings, separated by at least 5 days (Screening and Day 1)
  • DSS score \< 13 on two consecutive ratings, separated by at least five days (Screening and Day 1)
  • CGI-S score \< 3 on two consecutive ratings, separated by at least five days (Screening and Day 1)
  • Serum valproate level > 45 mcg/mL, and a maximum allowable dose of Depakote of 3000 mg/day at Screening
  • Olanzapine dose between 5 and 20 mg/day at Screening

Exclusion criteria

Exclusion Criteria:

  • History of schizophrenia or schizoaffective disorder
  • Axis I (e.g., anxiety disorder) or Axis II (e.g., personality disorder) that would interfere with compliance or confound interpretation of study results
  • Has taken antipsychotics, mood stabilizers, or anticonvulsants (unless specifically for seizure control) other than Depakote or olanzapine in the four months prior to randomization. Other psychotropics (e.g., antidepressants, anxiolytics) with the exception of stimulants, that have been used routinely to maintain stability in the preceding four months may be continued, but not increased or decreased
  • Has first manic episode after age 60
  • Has ever taken clozapine
  • Has received depot neuroleptic medication within six months of randomization
  • Urine toxicology screen is positive for phencyclidine (PCP), opiates, cocaine or amphetamines
  • History of active alcohol or substance abuse/dependence within 90 days prior to Screening
  • Known history of non-response to either Depakote or olanzapine monotherapy for the treatment of bipolar disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
180 participants
06

What researchers measure

Primary outcomes

  1. CGI-s

  2. CGI-i

  3. MRS

  4. DSS

  5. SADS-C

07

Study locations

15 sites
  • Behavioral and Medical Research, LLC
    Anaheim, California 92805, United States
  • Synergy Clinical Research
    Chula Vista, California 91910, United States
  • Clinical Trial Management
    Fort Meyers, Florida 33907, United States
  • Segal Institute for Clinical Research
    North Miami, Florida 33161, United States
  • Rush Presbyterian - St. Luke's
    Chicago, Illinois 60612, United States
  • University of Louisville Outpatient Psychiatry
    Louisville, Kentucky 40202, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Creighton University Department of Psychiatry
    Omaha, Nebraska 68131, United States
  • Lake Mead Hospital
    North Las Vegas, Nevada 89030, United States
  • NYU School of Medicine
    New York City, New York 10016, United States
  • University Hospital of Cleveland
    Cleveland, Ohio 44106, United States
  • R. Ranjan, MD & Associates, Inc.
    Lyndhurst, Ohio 44124, United States
  • IPS Research
    Oklahoma City, Oklahoma 73103, United States
  • UTMB Dept. of Psychiatry
    Galveston, Texas 77555-0197, United States
  • Zablocki VAMC
    Milwaukee, Wisconsin 53295, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 4, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00071253
Lead sponsor
Abbott
First posted
Oct 20, 2003
Start date
Jul 2003
Last update
Aug 4, 2006

Study contacts

Global Medical Information
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion